Study guide
15.7 Polycystic Ovary Syndrome
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
15.7 Polycystic Ovary Syndrome
Key Takeaways Explain This Topic AI
Rotterdam criteria require two of three: oligo-ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology.
Polycystic ovarian morphology is defined as 20 or more follicles of 2 to 9 mm per ovary or an ovarian volume of 10 mL or more.
Hirsutism is quantified by the modified Ferriman-Gallwey score, with 8 or more defining hirsutism in White and Black individuals and 4 to 6 in Asian individuals.
PCOS is a diagnosis of exclusion requiring an early morning 17-hydroxyprogesterone to rule out non-classic congenital adrenal hyperplasia, plus TSH and prolactin.
Chronic unopposed estrogen from anovulation makes endometrial hyperplasia and carcinoma a central long-term risk, so cyclic or continuous progestin is required even without fertility goals.
Last updated: September 2026
Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS) is the most prevalent endocrine disorder in reproductive-age individuals, affecting 6% to 15% of females worldwide. It is a heterogeneous, multi-system disorder driven by neuroendocrine dysfunction, hyperandrogenism, and metabolic insulin resistance.
Rotterdam Consensus Diagnostic Criteria
Diagnosis requires the presence of at least two of the following three features , provided other simulating disorders are systematically excluded:
Oligo- or Anovulation: Menstrual cycles >35 days apart or <8 cycles per calendar year.
Clinical and/or Biochemical Hyperandrogenism:
Clinical: Moderate-to-severe inflammatory acne, androgenic alopecia, and hirsutism. Hirsutism is objectively quantified using the modified Ferriman-Gallwey (mFG) score (assessing terminal hair growth in 9 androgen-sensitive body areas; a score ≥8 in White/Black individuals or ≥4 to 6 in Asian individuals defines hirsutism).
Biochemical: Elevated total testosterone, free testosterone, or dehydroepiandrosterone sulfate (DHEA-S).
Polycystic Ovarian Morphology (PCOM) on Ultrasound:
High-resolution transvaginal ultrasound demonstrating ≥20 follicles per ovary measuring 2 to 9 mm in diameter ("string of pearls" sign), OR an increased ovarian volume ≥10 mL in either ovary (excluding dominant follicles >10 mm or corpora lutea).
Mandatory Differential Exclusions
PCOS remains a diagnosis of exclusion. The nurse-midwife must rule out mimic disorders before confirming the diagnosis:
Non-Classic Congenital Adrenal Hyperplasia (NCAH): Measure early morning fasting 17-hydroxyprogesterone (17-OHP) . A level <200 ng/dL reliably excludes 21-hydroxylase deficiency; levels >200 ng/dL warrant an ACTH stimulation test.
Cushing Syndrome: Screen with 24-hour urinary free cortisol or late-night salivary cortisol if moon facies, purple abdominal striae, buffalo hump, or severe hypertension are present.
Androgen-Secreting Tumors: Consider if virilization is rapid, abrupt, or severe (clitoromegaly, deepening voice, temporal balding), or total testosterone is markedly elevated (>150–200 ng/dL) or DHEA-S >700–800 mcg/dL. Image ovaries and adrenals.
Thyroid Disease & Hyperprolactinemia: Exclude via TSH and serum prolactin.
Pathophysiology & Metabolic Sequelae
The core pathophysiology is a vicious metabolic-endocrine loop:
Hyperinsulinemia & Insulin Resistance: Peripheral insulin resistance in skeletal muscle and adipose tissue leads to compensatory hyperinsulinemia. High insulin acts synergistically with elevated LH pulses to stimulate ovarian theca cell androgen production . Concurrently, hyperinsulinemia suppresses hepatic synthesis of Sex Hormone-Binding Globulin (SHBG) , causing a dramatic surge in bioavailable free testosterone .
Cardiometabolic Consequences: Up to 70% of PCOS patients exhibit insulin resistance; 30% to 40% develop impaired glucose tolerance or overt Type 2 Diabetes Mellitus by age 40. Patients have an elevated incidence of metabolic syndrome, atherogenic dyslipidemia (low HDL, high triglycerides), nonalcoholic fatty liver disease (NAFLD / MASLD), obstructive sleep apnea, and vascular endothelial dysfunction. Screening with a fasting lipid panel and a 75-gram 2-hour Oral Glucose Tolerance Test (OGTT) is recommended every 1 to 3 years.
Endometrial Cancer Risk: Chronic, unmitigated anovulation deprives the endometrium of cyclic progesterone. Unopposed estrogen promotes unbridled endometrial epithelial proliferation, increasing the relative risk of endometrial adenocarcinoma 3- to 5-fold .
- Comprehensive Midwifery Management PCOS Stepwise Clinical Management
- ├── Foundational First-Line: Lifestyle Modification (5% - 10% Weight Loss)
- │ └── Restores spontaneous ovulation, reduces hyperinsulinemia, increases SHBG
- ├── Cycle Regulation & Endometrial Protection (Non-Pregnancy Seeking)
- │ ├── Combined Oral Contraceptives (COCs - Preferred First-Line)
- │ │ └── Ethinyl estradiol suppresses LH & boosts SHBG; progestin protects endometrium
- │ ├── 52 mg Levonorgestrel IUD (LNG-IUD) or Cyclic Oral Progestins
- │ │ └── Excellent endometrial protection if COCs contraindicated or not tolerated
- │ └── Metformin (500–2,000 mg/day)
- │ └── Improves insulin sensitivity, reduces progression to T2DM, modest weight benefit
- ├── Dermatologic / Hyperandrogenism Management
- │ ├── COCs with low-androgenic progestin (drospirenone, desogestrel, norgestimate)
- │ └── Spironolactone (50–200 mg/day - Antiandrogen)
│ └── CAUTION: Teratogenic to male fetus; MANDATORY reliable contraception!
- └── Ovulation Induction for Fertility (Pregnancy Seeking)
- └── Letrozole (Aromatase inhibitor, 2.5–7.5 mg/day on Days 3–7) - First-Line agent
Lifestyle Intervention: Foundational therapy. A modest 5% to 10% reduction in total body weight significantly reduces visceral adiposity, restores spontaneous ovulatory menses in up to 50% of overweight patients, lowers circulating androgens, and enhances fertility.
Combined Oral Contraceptive Pills (COCs): First-line medical therapy for individuals not desiring immediate conception. The estrogen component suppresses pituitary LH secretion (reducing ovarian androgen synthesis) and dramatically elevates hepatic SHBG production, binding circulating free androgens. The progestin component induces cyclic endometrial shedding, neutralizing the risk of endometrial hyperplasia. Formulations with low-androgenic or antiandrogenic progestins ( drospirenone , norgestimate , or desogestrel ) are preferred.
Endometrial Protection Alternatives: For individuals with contraindications to estrogen (e.g., migraine with aura, hypertension, history of VTE), the 52 mg LNG-IUD delivers potent, continuous local progestin that prevents hyperplasia for up to 8 years. Alternatively, prescribe cyclic oral progestins: Medroxyprogesterone acetate 10 mg PO daily for 12 to 14 days every 1 to 3 months , or oral micronized progesterone 200 mg nightly for 12 to 14 days .
Metformin: An insulin-sensitizing biguanide (titrated from 500 mg up to 1,500–2,000 mg daily). Indicated for PCOS individuals with impaired glucose tolerance, metabolic syndrome, or prediabetes. It modestly lowers fasting insulin, reduces free testosterone, and can facilitate weight loss.
Spironolactone: An aldosterone antagonist with potent antiandrogenic activity (blocks androgen receptors and inhibits 5α-reductase). Dosages of 50 to 200 mg daily significantly reduce hirsutism and inflammatory acne over a 6- to 12-month trial.
Critical Midwifery Practice Point: Spironolactone can cause feminization of the external genitalia in a developing male fetus. It must always be co-prescribed with highly effective contraception (e.g., COCs, IUD, or implant).
Ovulation Induction for Fertility: Per the landmark NICHD PPCOS II trial, Letrozole (an aromatase inhibitor, 2.5 to 7.5 mg daily on cycle days 3 to 7) is the first-line pharmacologic agent for ovulation induction in PCOS, demonstrating significantly higher live-birth rates (27.5% vs. 19.1%) and ovulation rates compared to clomiphene citrate, along with a lower incidence of high-order multiple gestations.